Login / Signup

[Iron deficiency anemia in a patient with hereditary hemorrhagic telangiectasia. Case report].

M A MozdonR V PonomarevN V TsvetaevaA V ShabrinE I ErmachenkovaS E LarichevElena A Lukina
Published in: Terapevticheskii arkhiv (2023)
Rendu-Osler-Weber disease or hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease. It is characterized by vascular dysplasia with the formation of telangiectasias on the skin, mucous membranes of the respiratory and digestive tracts, arteriovenous malformations (AVMs) in the internal organs, which is manifested by bleeding. Diagnosis is based on Curacao criteria: recurrent and spontaneous nosebleeds, multiple telangiectases on the characteristic localizations, AVMs in one or more of the internal organs, a family history of HHT (i.e. first-degree relative who meets these same criteria for definite HHT). Therapy is aimed at preventing and stopping gastrointestinal, nosebleeds, correction of iron deficiency anemia. A promising method of therapy is the use of angiogenesis inhibitors, in particular bevacizumab. The article presents a description of a clinical case of HHT in a 49-year-old woman with telangiectisia on the mucous membrane of the tongue, gastrointestinal tract and liver AVMs.
Keyphrases
  • iron deficiency
  • case report
  • atrial fibrillation
  • endothelial cells
  • stem cells
  • vascular endothelial growth factor
  • mesenchymal stem cells
  • cell therapy